Full-Time

Regulatory Affairs Director

Oncology

Confirmed live in the last 24 hours

AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

Compensation Overview

$159.4k - $239.1k/yr

+ Bonus + Equity-based long-term incentive program

Senior, Expert

New York, NY, USA

Employees are expected to work in the office 3 days a week.

Category
Risk & Compliance
Legal & Compliance
Required Skills
Marketing
Requirements
  • An advanced degree in a science related field and/or other appropriate knowledge/experience
  • A solid knowledge of regulatory affairs within at least one therapeutic area in early and late development
  • Previous demonstrated experience of regulatory drug development or equivalent, and experience with major HA interactions
  • Demonstrated competencies of strategic thinking, strategic influencing, risk evaluation, innovation, initiative, leadership and excellent oral and written communication skills
  • The ability to think strategically and critically and evaluate risks to regulatory activities.
Responsibilities
  • Lead cross functional teams in major regulatory submissions (NDA/BLA/IND/CTA), health authority interactions, label discussions, and securing approvals.
  • Develop and implement the program's regional or global strategy ensuring that it is crafted to deliver rapid approval with competitive labelling that is identified by the business, markets and patients.
  • Craft the health authority engagement strategy and interaction plan, drive the formulation of the briefing document focused on strategy and scientific content, lead the team through meeting rehearsals and moderate the meeting itself.
  • Lead a Global Regulatory Strategy Team (GRST) of key contributing members from the regions, emerging markets, RA CMC, Labelling and members of the submission and execution team. Mentor and provide performance feedback to members of your GRST.
  • Deliver regulatory milestones on your team including an assessment of risks and mitigations, emerging data, and the probability of success. Lead preparation of the regulatory strategy document and target product labelling.
  • Own the negotiations with health authorities and initiate and deliver key regulatory documents.
  • Plan and construct the global dossier and core prescribing information including product maintenance, supply and compliance activities.
  • Partner with marketing companies (countries) and regional regulatory affairs staff to influence developing views/guidance.
Desired Qualifications
  • Experience in Oncology (small molecules & biologics)
  • Prior experience with phase 3 design including end of phase 2 health authority interactions
  • Contribution to a regulatory approval including leading response team and labelling negotiations
  • Knowledge and understanding of guiding principles in drug development such as benefit/risk profile, dose selection or statistical design
  • Broad background of experience working in pharmaceutical business and prior experience in several areas within regulatory affairs
  • Ability to work strategically within a business critical and high-profile development program
  • Critical thinking on current global regulatory science questions and good understanding of the corresponding scientific and clinical component.

AstraZeneca focuses on discovering, developing, and selling prescription medicines. The company specializes in three main areas: Oncology, which deals with cancer treatment; Cardiovascular, Renal & Metabolism, which addresses heart, kidney, and metabolic diseases; and Respiratory & Immunology, which targets lung and immune system diseases. Their products are developed through extensive research and development, followed by clinical trials and regulatory approvals before reaching the market. AstraZeneca distinguishes itself from competitors by investing heavily in scientific research and fostering collaborations through initiatives like their Open Innovation program, which shares resources with the scientific community to speed up drug discovery. The company's goal is to advance healthcare by creating effective treatments for serious diseases and expanding their product offerings through strategic partnerships.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-powered tools enhance AstraZeneca's lung cancer detection capabilities, improving early diagnosis.
  • Enhertu shows significant improvement in breast cancer treatment, boosting AstraZeneca's oncology portfolio.
  • Calquence's EU approval for CLL offers a competitive edge in leukemia treatment.

What critics are saying

  • Discontinuation of CAPItello-280 trial impacts AstraZeneca's oncology pipeline and investor confidence.
  • Operational challenges at the new CAR-T facility may delay cell therapy production.
  • AI reliance in lung cancer detection poses risks related to data privacy and accuracy.

What makes AstraZeneca unique

  • AstraZeneca's Open Innovation program accelerates drug discovery through shared compounds and technologies.
  • The A.Catalyst Network fosters global collaboration and innovation in health through 20+ hubs.
  • AstraZeneca's focus on Oncology, Cardiovascular, and Respiratory areas sets it apart in biopharma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

MocoShow
May 9th, 2025
AstraZeneca Opens $300 Million CAR-T Manufacturing Facility in Rockville, Creating Over 150 Jobs

AstraZeneca opens $300 million CAR-T manufacturing facility in Rockville, creating over 150 jobs.

Cision
May 9th, 2025
Imfinzi Improved Dfs In Early Bladder Cancer

Imfinzi improved DFS in early bladder cancer

PharmiWeb
May 7th, 2025
Enhertu Followed By Thp Before Surgery Showed Statistically Significant And Clinically Meaningful Improvement In Pathologic Complete Response In Patients With High-Risk Her2-Positive Early-Stage Breast Cancer In Destiny-Breast11 Phase Iii Trial

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer. Positive high-level results from the DESTINY-Breast11 Phase III trial showed Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment. The secondary endpoint of event-free survival (EFS) was not mature at the time of analysis; however, EFS data showed an early positive trend favouring Enhertu followed by THP compared to standard of care. The trial will continue to follow EFS

Cision
May 7th, 2025
Enhertu Improved Pcr In Early-Stage Breast Cancer

Enhertu improved pCR in early-stage breast cancer

Bethesda Magazine
May 6th, 2025
AstraZeneca opens cell therapy manufacturing site in Rockville

AstraZeneca announced in February 2024 that it was investing in the Rockville manufacturing facility.